We previously demonstrated recipient-derived neoangiogenesis to maintain viability of living bone allogeneic transplants without long-term immunosuppression. The effect of cytokine delivery to enhance this process is studied.
Vascularized femur transplantation was performed from DA to PVG rats. Poly(D,L-lactide-co-glycolide) microspheres loaded with buffer (N=11), basic fibroblast growth factor (FGF2) (N=10), vascular endothelial growth factor (VEGF) (N=11), or both (N=11) were inserted intramedullarly alongside a recipient-derived a/v bundle. FK-506 was administered for 2 weeks. At 18 weeks, bone blood flow, microangiography, histologic, histomorphometric and alkaline phosphatase measurements were performed.
Bone blood flow was greater in the combined group than control and VEGF groups (p=0.04). Capillary density was greater in the FGF2 group than in the VEGF and combined groups (p<0.05). Bone viability, growth and alkaline phosphatase activity did not vary significantly between groups.
Neoangiogenesis in vascularized bone allotransplants is enhanced by angiogenic cytokine delivery, with results using FGF2 that are comparable to isotransplant from previous studies. Further studies are needed to achieve bone formation similar to isotransplants.